Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$51.73 USD

51.73
1,388,647

+0.47 (0.92%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $51.74 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Lilly's (LLY) Tirzepatide Meets Endpoints in Late-Stage Study

by Zacks Equity Research

Lilly's (LLY) tirzepatide demonstrates superiority in improving blood sugar levels and reducing body-weight compared to placebo in a phase III study evaluating in type 2 diabetes patients.

Glaxo's (GSK) Nucala Filing for Nasal Polyps Accepted by FDA

by Zacks Equity Research

The FDA accepts Glaxo's (GSK) regulatory filing for Nucala to treat patients with chronic rhinosinusitis with nasal polyps. The drug is already approved for three other indications.

Regeneron (REGN) Posts Upbeat Data on Myeloma Candidate at ASH

by Zacks Equity Research

Regeneron (REGN) releases encouraging data from early-stage study on REGN5458 at the ASH 2020.

Regeneron (REGN), Sanofi Win EC Nod for Dupixent Label Expansion

by Zacks Equity Research

Regeneron (REGN) and Sanofi win EC nod for Dupixent for the indication of severe atopic dermatitis in children 6 to 11 years of age.

Kinjel Shah headshot

Pharma Stock Roundup: AZN COVID-19 Vaccine Interim Data, PFE Emergency Use Appeal

by Kinjel Shah

AstraZeneca (AZN) COVID-19 vaccine candidate proves effective in late-stage study. Pfizer (PFE) seeks Emergency use for its COVID-19 vaccine candidate.

Sanofi's (SNY) Meningitis Vaccine MenQuadfi Wins EU Approval

by Zacks Equity Research

The European Commission nods to Sanofi's (SNY) MenQuadfi, a meningococcal vaccine for individuals, aged 12 months and older.

Glaxo's (GSK) RSV Vaccine for Pregnant Women Enters Phase III

by Zacks Equity Research

Glaxo (GSK) is developing vaccine against respiratory syncytial virus for pediatric patients, pregnant women and older adults. The candidates hold significant potential.

Kinjel Shah headshot

Pharma Stock Roundup: PFE COVID-19 Vaccine Final Analysis, FDA Updates & More

by Kinjel Shah

Pfizer (PFE) COVID-19 vaccine candidate proves to be 95% effective in final analysis. Sanofi (SNY), Lilly (LLY), Merck (MRK) & Glaxo (GSK) provide FDA updates.

Sanofi (SNY) Pompe Disease Drug Gets FDA's Priority Tag

by Zacks Equity Research

The FDA gives priority review tag to Sanofi's (SNY) avalglucosidase alfa for Pompe disease and Fast Track status to rilzabrutinib for immune thrombocytopenia.

Sanofi (SNY) Blood Disorder Candidate Gets FDA's Rejection

by Zacks Equity Research

The FDA gives a complete response letter to Sanofi's (SNY) regulatory application for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease.

Novavax (NVAX) Loss Widens in Q3, Revenues Lag Estimates

by Zacks Equity Research

Novavax's (NVAX) bottom line deteriorates year over year in the third quarter of 2020. Revenues fall shy of estimates as well. Stock dips in after-hours trading.

Emergent (EBS) Beats on Q3 Earnings, Tapers '20 Sales View

by Zacks Equity Research

Emergent (EBS) beats on earnings in Q3 while revenues miss estimates. Total product sales fall year over year and the company tightens its revenue guidance. Stock slides in after-hours trading.

BioMarin (BMRN) Beats on Q3 Earnings, Lowers Sales View

by Zacks Equity Research

BioMarin (BMRN) beats estimates for both earnings and sales in the third quarter. The company lowers its sales guidance for 2020.

Regeneron's (REGN) Q3 Earnings & Sales Surpass Estimates

by Zacks Equity Research

Regeneron (REGN) beats on both earnings and sales in the third quarter of 2020 on strong performances by Eylea and Dupixent. Shares rise in pre-market trading.

Kinjel Shah headshot

Pharma Stock Roundup: Q3 Earnings, Resumption of AZN/JNJ Coronavirus Vaccine Study

by Kinjel Shah

Eli Lilly (LLY), Merck (MRK), Pfizer (PFE), Novartis (NVS) and others release Q3 results

Novo Nordisk's (NVO) Q3 Earnings Beat Estimates, Sales Miss

by Zacks Equity Research

Novo Nordisk (NVO) misses earnings and sales estimates in the third quarter of 2020.

What's in the Cards for Regeneron's (REGN) Q3 Earnings?

by Zacks Equity Research

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports third-quarter 2020 results.

Sanofi's (SNY) Q3 Earnings & Sales Miss, 2020 View Raised

by Zacks Equity Research

Sanofi's (SNY) earnings and sales miss estimates. It raises its earnings growth expectations for the year.

Can Coronavirus Vaccine Efforts Aid Novavax (NVAX) Q3 Earnings?

by Zacks Equity Research

During Novavax's (NVAX) upcoming third-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate NVX-CoV2373.

The Zacks Analyst Blog Highlights: Amazon, Home Depot, Sanofi, Intel and AMT

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Amazon, Home Depot, Sanofi, Intel and AMT

Are Investors Undervaluing Sanofi (SNY) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

SNY or NVO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

SNY vs. NVO: Which Stock Is the Better Value Option?

Regeneron's (REGN) Dupixent Gets Positive CHMP Opinion for Dermatitis

by Zacks Equity Research

Regeneron (REGN) gets positive CHMP opinion for Dupixent, recommending extending the approval in the European Union to include children aged 6 to 11 years with severe atopic dermatitis.

Roche (RHHBY), AbbVie's Leukemia Drug Venclexta Get Full FDA Nod

by Zacks Equity Research

Roche (RHHBY) and partner AbbVie obtain full FDA approval for leukemia drug, Venclexta, in combination with Vidaza or Dacogen or low-dose cytarabine (LDAC).

Sheraz Mian headshot

Top Stock Reports for Amazon, Home Depot & Sanofi

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com (AMZN), The Home Depot (HD) and Sanofi (SNY).